GlassScriptPhysician profile
Delaney Baumann
NPI 1851891667
$2,975.56
in general payments reported to CMS, 2019-2025
19 companies · $171 in 2025
The $171 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $341 · 2022: $1,128 · 2023: $1,322 · 2024: $13.69 · 2025: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,498 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,498.04 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,473.53 | 2021-2025 | |
| Lilly USA, LLC | $231.45 | 2022-2023 | Mounjaro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $179.78 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $168.02 | 2023 | Auvelity, Sunosi |
| Amgen INC. | $153.47 | 2021-2023 | Evenity, Prolia |
| Novo Nordisk INC | $140.27 | 2022-2023 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $129.70 | 2023 | Shingrix, Trelegy Ellipta, Bexsero |
| Astrazeneca Pharmaceuticals LP | $106.07 | 2022-2023 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $101.60 | 2022 | |
| Supernus Pharmaceuticals, INC. | $56.32 | 2022-2023 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $48.63 | 2022-2023 | Trintellix |
| Bausch Health US, LLC | $43.56 | 2022-2023 | Aplenzin, Wellbutrin |
| Astellas Pharma US INC | $32.71 | 2022-2023 | Myrbetriq |
| Corium, LLC | $22.82 | 2023 | Azstarys |
| Sanofi-Aventis U.S. LLC | $20.36 | 2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $19.80 | 2023 | Eliquis |
| Exact Sciences Corporation | $18.31 | 2023 | Cologuard Collection Kit |
| Pfizer INC. | $15.80 | 2023 | |
| Idorsia Pharmaceuticals US INC | $13.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Delaney Baumann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.